

Evaluation of Target Definition by Multimodality Imaging for Management of Low-Lying Rectal Cancer with Short Course Radiation Therapy (SCRT)

Esin Gundem^{1*} and Yelda Elcim²

¹Department of Radiation Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Turkey

²Gulhane Training and Research Hospital, University of Health Sciences, Gulhane Medical Faculty, Department of Radiation Oncology, Turkey

*Corresponding author: Esin Gundem, Gulhane Training and Research Hospital, University of Health Sciences, Gulhane Medical Faculty, Department of Radiation Oncology, Ankara, Turkey



ARTICLE INFO

Received: 📅 March 22, 2022

Published: 📅 April 01, 2022

Citation: Esin Gundem, Yelda Elcim. Evaluation of Target Definition by Multimodality Imaging for Management of Low-Lying Rectal Cancer with Short Course Radiation Therapy (SCRT). Biomed J Sci & Tech Res 43(1)-2022. BJSTR. MS.ID.006841.

Abbreviations: SCRT: Short Course Radiation Therapy; CT: Computed Tomography; RT: Radiation Therapy; TME: Total Mesorectal Excision; MRI: Magnetic Resonance Imaging; TPS: Treatment Planning System; IGRT: Image Guided RT; ART: Adaptive Radiation Therapy; IMRT: Intensity Modulated RT; BART: Breathing Adapted Radiation Therapy

ABSTRACT

Objective: Short Course Radiation Therapy (SCRT) may allow for minimizing treatment visits which may improve patient and treatment facility convenience under the special circumstances of COVID-19 pandemic. Given the importance of precise target definition in the context of SCRT, we herein assess multimodality imaging for target definition of low-lying rectal cancers.

Materials and Methods: Contribution of multimodality imaging on target definition of low-lying rectal cancer was assessed. All included patients underwent Computed Tomography (CT)-simulation, and target definition was performed by use of CT-simulation images only or by incorporation of Magnetic Resonance Imaging (MRI).

Results: Determination of ground truth target volume has been performed after meticulous evaluation, detailed collaborative assessment, colleague peer review, and consensus by board certified radiation oncologists. Our study with the primary focus on target definition by CT-only imaging and by CT-MR registration based imaging has revealed that target definition by CT-MR registration based imaging was identical with the ground truth target volume for low-lying rectal cancer.

Conclusion: Utilization of multimodality imaging data for improved visualization and use of sophisticated image registration and fusion techniques may assist in accurate target definition for SCRT of low-lying rectal cancer despite the need for further supporting evidence.

Keywords: Low-Lying Rectal Cancer; Short Term Radiation Therapy (SCRT); Magnetic Resonance Imaging (MRI)

Introduction

Colorectal cancers are among the most frequent cancers worldwide [1,2]. Rectal cancer composes a significant proportion of colorectal cancers, and low-lying rectal cancers are an important subgroup possessing different characteristics. Patients with rectal

cancer may have a plethora of symptoms which may profoundly deteriorate quality of life. Also, morbidity and mortality due to rectal cancer is not uncommon. Within this context, rigorous management of rectal cancer is warranted to achieve optimal patient outcomes. Currently, surgical resection, systemic therapies, and Radiation

Therapy (RT) may be utilized alone or in combination with respect to disease stage, patient, tumor, and treatment characteristics. Total Mesorectal Excision (TME) has been introduced as a viable modality of surgical management leading to improved treatment results and is widely accepted as a prominent surgical approach [3]. In the context of irradiation, both short course RT (SCRT) and long course RT may be feasible and may be utilized after thorough patient evaluation and selection [4]. The recent coronavirus disease 2019 (COVID-19) pandemic came up with some administrative measures which led to modifications in treatment facility practice patterns to a large extent.

SCRT may allow for minimizing treatment visits which may improve patient and treatment facility convenience under the special circumstances of COVID-19 pandemic. Nevertheless, larger fraction size and high fractional doses should be used vigilantly to refrain from adverse radiation effects. Any deviation from accuracy in target definition may result in treatment failure or untowards toxicity. Given the importance of precise target definition in the context of SCRT, we herein assess multimodality imaging for target definition of low-lying rectal cancers.

Materials and Methods

Patients referred for SCRT for low-lying rectal cancer following thorough multidisciplinary assessment were included with consideration of suggested therapeutic strategies, patient, tumor, and treatment related features. Lesion size, localization and association with surrounding critical structures was taken into account along with symptomatology and expected outcomes of SCRT. Contribution of multimodality imaging on target definition of low-lying rectal cancer was assessed in terms of interobserver and intraobserver variations. All included patients underwent Computed Tomography (CT)-simulation, and target definition was performed by use of CT-simulation images only or by incorporation of Magnetic Resonance Imaging (MRI). A prominent group of experts have defined the ground truth target volume to be utilized for actual treatment and comparative evaluation. In this context, thorough patient assessment was performed with colleague peer review and consensus. Following treatment simulation at the CT-simulator (GE Lightspeed RT, GE Healthcare, Chalfont St. Giles, UK), acquired planning images have been transferred to the contouring workstation (SimMD, GE, UK) via the network for delineation of treatment volumes and critical structures.

We have used either CT-simulation images only or registered CT and MR images for target definition of low-lying rectal cancer. Comparative analysis has been performed to assess target definition by CT only and with incorporation of CT-MR registration. Individualized treatment dose calculation has been performed

in the Treatment Planning System (TPS) unit by accounting for electron density, CT number and HU values in CT images with consideration of tissue heterogeneities. Synergy (Elekta, UK) linear accelerator (LINAC) was used for SCRT with daily incorporation of image guidance by electronic digital portal imaging and kilovoltage cone beam CT.

Results

Critical organ dose limitations were considered on an individual basis and requirements of optimal treatment planning were taken into account in light of recent guidelines along with reports of American Association of Physicists in Medicine (AAPM) and International Commission on Radiation Units and Measurements (ICRU). Treatment dose calculation has been carried out by considering the tissue heterogeneity, electron density, CT number and HU values in CT images. Coverage of treatment volumes has been a priority in treatment planning by expert radiation physicists while maintaining optimal normal tissue sparing. Determination of ground truth target volume has been performed after meticulous evaluation, detailed collaborative assessment, colleague peer review, and consensus by board certified radiation oncologists. We used the ground truth target volume for actual treatment and also for comparative evaluation. Treatment delivery has been accomplished by use of Synergy (Elekta, UK) LINAC with daily integration of image guidance by kilovoltage cone beam CT and electronic digital portal imaging. Our study with the primary focus on target definition by CT-only imaging and by CT-MR registration based imaging has revealed that target definition by CT-MR registration based imaging was identical with the ground truth target volume for low-lying rectal cancer.

Discussion

Colorectal cancer comprises a major public health concern as a leading cause of cancer related morbidity and mortality around the globe [1,2]. Among the group of colorectal cancers, low-lying rectal tumors require utmost attention with their characteristics. Prognosis for low-lying rectal cancers may be relatively poorer. This may be in part due to difficulties in surgical management, absence of peritoneum as a barrier to tumor spread, and possible tendency for systemic metastases. Within this context, optimal management of low-lying rectal cancer poses a formidable challenge to the treating physicians. Surgical techniques, systemic therapy strategies, and RT have evolved over time and significant advances have occurred in recent years. COVID-19 pandemic has resulted in critical modifications in treatment practice, and the utility of SCRT has been revisited in the meantime. Improving patient and treatment facility convenience under the special circumstances of COVID-19 pandemic has been a critical endpoint in decision making

for patient management. In the context of rectal cancer, SCRT has been well recognized within the scientific community as a viable mode of radiotherapeutic management.

Using condensed treatment schedules has been more popular during the COVID-19 pandemic with shorter overall treatment time. This may clearly have implications for improved utilization of available sources, reduced contact and treatment visits under the special circumstances of COVID-19 pandemic. Nevertheless, the utility of SCRT has been assessed for rectal cancer for a long time, and its safety and efficacy as a viable alternative to long course RT has been supported by high level evidence [4]. Clearly, the use of large fraction size and high fractional doses should be performed vigilantly. Image guidance and image registration methods may aid in improving radiotherapeutic management. Target definition composes an integral part of optimal radiotherapeutic management. While determination of larger than actual treatment volumes may profoundly increase toxicity, definition of smaller than actual treatment volumes may lead to geographic misses and resultant treatment failures. In the awareness of this critical situation, there is need for exploiting the advantage of multimodality imaging. CT has the inherent limitation of low contrast resolution which renders detailed assessment of rectal wall layers and the sphincter rather complex.

MRI with appropriate slice thickness may significantly improve rectal cancer imaging for RT target definition [5,6]. In clinical practice, CT-simulation is typically performed for radiation treatment planning in majority of cancer therapy centers. MRI may provide additional information which may assist is precise and accurate target definition. The superior contrast resolution of MRI may offer several clinical implications regarding SCRT for low-lying rectal cancer. Currently, there has been an increasing trend towards utilization of multimodality imaging for improved target definition of several tumors throughout the human body [7-41]. From this perspective, this study may add to the growing body of evidence regarding the incorporation of multimodality imaging based target definition for SCRT of low-lying rectal cancer. Recent years have witnessed several improvements in radiation oncology discipline with incorporation of contemporary therapeutic equipment and adaptive irradiation strategies, Image Guided RT (IGRT), Adaptive Radiation Therapy (ART), Intensity Modulated RT (IMRT), Breathing Adapted Radiation Therapy (BART), molecular imaging methods, automatic segmentation techniques, and stereotactic RT [42-78]. For the meantime, introduction of sophisticated RT approaches comprises an evolving area of active investigation and there may still be room for future advances.

In conclusion, utilization of multimodality imaging data for improved visualization and use of sophisticated image registration

and fusion techniques may assist in accurate target definition for SCRT of low-lying rectal cancer despite the need for further supporting evidence.

Conflict of Interest

There are no conflicts of interest and no acknowledgements.

References

1. Siegel R L, Miller K D, Fuchs H E, Jemal A (2022) Cancer statistics. *CA Cancer J Clin* 72: 7-33.
2. Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Prz Gastroenterol* 14: 89-103.
3. Votava J, Kachlik D, Hoch J (2020) Total mesorectal excision - 40 years of standard of rectal cancer surgery. *Acta Chir Belg* 120: 286-290.
4. Wang J, Long Y, Liu K, Pei Q, Zhu H, et al. (2021) Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer. *BMC Gastroenterol* 21(1): 277.
5. O Neill B D, Salerno G, Thomas K, Tait D M, Brown G (2009) MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. *Br J Radiol* 82(948): 509-513.
6. Gwynne S, Mukherjee S, Webster R, Spezi E, Staffurth J, et al. (2012) Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review. *Clin Oncol (R Coll Radiol)* 24(1): 52-63.
7. Beaton L, Bandula S, Gaze M N, Sharma R A (2019) How rapid advances in imaging are defining the future of precision radiation oncology. *Br J Cancer* 120(8): 779-790.
8. Stieb S, Mc Donald B, Gronberg M, Engeseth G M, He R, et al. (2019) Imaging for Target Delineation and Treatment Planning in Radiation Oncology: Current and Emerging Techniques. *Hematol Oncol Clin North Am* 33(6): 963-975.
9. Pereira G C, Traughber M, Muzic R F (2014) The role of imaging in radiation therapy planning: past, present, and future. *Biomed Res Int* 2014: 231090.
10. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging. *J Surg Surgical Res* 7: 42-46.
11. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Evaluation of Changes in Tumor Volume Following Upfront Chemotherapy for Locally Advanced Non Small Cell Lung Cancer (NSCLC). *Glob J Cancer Ther* 7: 31-34.
12. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Multimodality Imaging Based Treatment Volume Definition for Reirradiation of Recurrent Small Cell Lung Cancer (SCLC). *Arch Can Res* 9: 1-5.
13. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Assessment of the role of multimodality imaging for treatment volume definition of intracranial ependymal tumors: An original article. *Glob J Cancer Ther* 7: 43-45.
14. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Impact of Multimodality Imaging to Improve Radiation Therapy (RT) Target Volume Definition for Malignant Peripheral Nerve Sheath Tumor (MPNST). *Biomed J Sci Tech Res* 34: 26734-26738.
15. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2021) Radiation Therapy (RT) Target Volume Definition for Peripheral Primitive Neuroectodermal Tumor (PPNET) by Use of Multimodality Imaging: An Original Article. *Biomed J Sci & Tech Res* 34: 26970-26974.

16. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2021) Evaluation of Target Definition for Management of Myxoid Liposarcoma (MLS) with Neoadjuvant Radiation Therapy (RT). *Biomed J Sci Tech Res* 33: 26171-26174.
17. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Assessment of Multimodality Imaging for Target Definition of Intracranial Chondrosarcomas. *Canc Therapy Oncol Int J* 18: 001-005.
18. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Assessment of posterior fossa target definition by multimodality imaging for patients with medulloblastoma. *J Surg Surgical Res* 7: 37-41.
19. Dincoglan F, Beyzadeoglu M, Demiral S, Sager O (2020) Assessment of Treatment Volume Definition for Irradiation of Spinal Ependymomas: an Original Article. *ARC Journal of Cancer Science* 6: 1-6.
20. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Assessment of Target Volume Definition for Radiosurgery of Atypical Meningiomas with Multimodality Imaging. *Journal of Hematology and Oncology Research* 3: 14-21.
21. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2020) Multimodality Imaging Based Target Definition of Cervical Lymph Nodes in Precise Limited Field Radiation Therapy (Lfrt) for Nodular Lymphocyte Predominant Hodgkin Lymphoma (Nlph). *ARC Journal of Cancer Science* 6: 6-11.
22. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2020) Target Definition of orbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6: 12-17.
23. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2020) Utility of Multimodality Imaging Based Target Volume Definition for Radiosurgery of Trigeminal Neuralgia: An Original Article. *Biomed J Sci & Tech Res* 26: 19728-19732.
24. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Treatment Volume Determination for Irradiation of chordoma: an Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5(10): 3-8
25. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Assessment of Target Volume Definition for Irradiation of Hemangiopericytomas: An Original Article. *Canc Therapy & Oncol Int J* 17(2): 555959.
26. Beyzadeoglu M, Dincoglan F, Sager O, Demiral S (2020) Determination of Radiosurgery Treatment Volume for Intracranial Germ Cell Tumors (GCTS). *Asian Journal of Pharmacy, Nursing and Medical Sciences* 8: 18-23.
27. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2020) Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMs). *Canc Therapy & Oncol Int J* 15: 555917.
28. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Treatment Volume Determination for Irradiation of Recurrent Nasopharyngeal Carcinoma with Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6: 18-23.
29. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Evaluation of Radiosurgery Target Volume Definition for Tectal Gliomas with Incorporation of Magnetic Resonance Imaging (MRI): An Original Article. *Biomedical Journal of Scientific & Technical Research (BJSTR)* 27: 20543-20547.
30. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2020) Target Volume Determination for Precise Radiation Therapy (RT) of Central Neurocytoma: An Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5: 29-34.
31. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Radiosurgery Treatment Volume Determination for Brain Lymphomas with and without Incorporation of Multimodality Imaging. *Journal of Medical Pharmaceutical and Allied Sciences* 9: 2398-2404.
32. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Target Volume Determination for Irradiation of Pilocytic Astrocytomas: An Original Article. *ARC Journal of Cancer Science* 6: 1-5.
33. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Multimodality Imaging for Radiosurgical Management of Arteriovenous Malformations. *Asian Journal of Pharmacy, Nursing and Medical Sciences* 7: 7-12.
34. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S (2019) Evaluation of Target Definition for Stereotactic Reirradiation of Recurrent Glioblastoma. *Arch Can Res* 7(1): 3.
35. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Incorporation of Multimodality Imaging in Radiosurgery Planning for Craniopharyngiomas: An Original Article. *SAJ Cancer Sci* 6: 103.
36. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Utility of Magnetic Resonance Imaging (Imaging) in Target Volume Definition for Radiosurgery of Acoustic Neuromas. *Int J Cancer Clin Res* 6: 119.
37. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Radiosurgery Treatment Planning for Pituitary Adenomas. *Canc Therapy & Oncol Int J* 13: 555857.
38. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Evaluation of the Impact of Magnetic Resonance Imaging (MRI) on Gross Tumor Volume (GTV) Definition for Radiation Treatment Planning (RTP) of Inoperable High Grade Gliomas (HGGs). *Concepts in Magnetic Resonance Part A*.
39. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of target definition based on Multimodality imaging for radiosurgical Management of glomus jugulare tumors (GJTs). *Canc Therapy & Oncol Int J* 15: 555909.
40. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI). *Cancer Sci Res Open Access* 5: 1-4.
41. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2018) Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. *Canc Therapy & Oncol Int J* 12: 555848.
42. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2022) Optimal timing of thoracic irradiation for limited stage small cell lung cancer: Current evidence and future prospects. *World J Clin Oncol* 13: 116-124.
43. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Omission of Radiation Therapy (RT) for Metaplastic Breast Cancer (MBC): A Review Article. *International Journal of Research Studies in Medical and Health Sciences* 6: 10-15.
44. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2021) Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. *Indian J Cancer* 58(2): 195-200.
45. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Concise review of stereotactic irradiation for pediatric glial neoplasms: Current concepts and future directions. *World J Methodol* 11: 61-74.
46. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Gamsiz H, et al. (2020) Multimodality management of cavernous sinus meningiomas with less

- extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. *J Surg Surgical Res* 6: 56-61.
47. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Uysal B, et al. (2020) A Concise Review of Irradiation for Temporal Bone Chemodectomas (TBC). *Arch Otolaryngol Rhinol* 6: 16-20.
 48. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2020) Adaptive radiation therapy of breast cancer by repeated imaging during irradiation. *World J Radiol* 12(5): 68-75.
 49. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. (2020) Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated Stereotactic Radiotherapy (FSRT) for Vestibular Schwannoma (VS). *J Surg Surgical Res* 6: 062-066.
 50. Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, et al. (2019) Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. *Indian J Cancer* 56(3): 202-206.
 51. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Breathing adapted radiation therapy for leukemia relapse in the breast: A case report. *World J Clin Oncol* 10(11): 369-374.
 52. Dincoglan F, Sager O, Demiral S, Gamsiz H, Uysal B, et al. (2019) Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. *Indian J Cancer* 56(2): 151-156.
 53. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-D-Glucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. *Curr Radiopharm* 12(1): 4-10.
 54. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2018) Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. *Jpn J Radiol* 36(6): 401-406.
 55. Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, et al. (2018) Contemporary Management of Meningiomas with Radiosurgery. *Int J Radiol Imaging Technol* 80: 187-190.
 56. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2017) Splenic Irradiation: A Concise Review of the Literature. *J App Hem Bl Tran* 1: 101.
 57. Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, et al. (2017) Radiosurgery for recurrent glioblastoma: A review article. *Neurol Disord Therap* 1: 1-5.
 58. Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, et al. (2016) Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM). *Jpn J Radiol* 34(11): 730-737.
 59. Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, et al. (2015) Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. *Tumori* 101(1): 98-103.
 60. Sager O, Dincoglan F, Beyzadeoglu M (2015) Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. *CNS Oncol* 4(2): 105-114.
 61. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2015) Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. *Tumori* 101(1): 84-90.
 62. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, et al. (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Tumori* 101(2): 179-184.
 63. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2014) Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. *Tumori* 100(3): 302-306.
 64. Ozsavaş E E, Telatar Z, Dirican B, Sager O, Beyzadeoglu M (2014) Automatic segmentation of anatomical structures from CT scans of thorax for RTP. *Comput Math Methods Med* 2014: 472890.
 65. Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, et al. (2014) Management of pulmonary oligometastases by stereotactic body radiotherapy. *Tumori* 100(2): 179-183.
 66. Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, et al. (2014) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. *Tumori* 100(2): 184-188.
 67. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of Linear Accelerator (Linac)-Based Stereotactic Radiosurgery (Srs) for the Treatment of Craniopharyngiomas. *UHOD-Uluslararası Hematoloji Onkoloji Dergisi* 24(2): 123-129.
 68. Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, et al. (2014) Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. *Ann Saudi Med* 34(1): 54-58.
 69. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, et al. (2013) Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. *Tumori* 99(1): 76-82.
 70. Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, et al. (2013) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. *J BUON* 18(3): 717-722.
 71. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2013) Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience. *Tumori* 99(5): 617-622.
 72. Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, et al. (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. *Neoplasma* 60(3): 322-327.
 73. Sager Ö, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. (2012) Evaluation of the impact of integrated [18f]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging on staging and radiotherapy treatment volume definition of non-small cell lung cancer. *Gulhane Med J* 54: 220-227.
 74. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2012) Stereotactic radiosurgery for intracranial tumors: A single center experience. *Gulhane Med J* 54: 190-198.
 75. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S, et al. (2012) Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. *Tumori* 98(5): 630-635.
 76. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy. *Neoplasma* 59(3): 333-340.
 77. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) The Role of Active Breathing Control-Moderate Deep Inspiration Breath-Hold (ABC-mDIBH) Usage in non-Mastectomized Left-sided Breast Cancer Radiotherapy: A Dosimetric Evaluation UHOD - Uluslararası Hematoloji-Onkoloji Dergisi 22: 147-155.
 78. Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, et al. (2011) Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. *Vojnosanit Pregl* 68(11): 961-966.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2022.43.006842

Esin Gundem. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>